Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data
暂无分享,去创建一个
[1] Weihsueh A. Chiu,et al. Well-tempered MCMC simulations for population pharmacokinetic models , 2020, Journal of Pharmacokinetics and Pharmacodynamics.
[2] H. Koch,et al. Hexamoll® DINCH and DPHP metabolites in urine of children and adolescents in Germany. Human biomonitoring results of the German Environmental Survey GerES V, 2014-2017. , 2020, International journal of hygiene and environmental health.
[3] T. Brüning,et al. Metabolism and urinary excretion kinetics of di(2-ethylhexyl) adipate (DEHA) in four human volunteers after a single oral dose. , 2019, Toxicology letters.
[4] George Loizou,et al. Development, Testing, Parameterization, and Calibration of a Human Physiologically Based Pharmacokinetic Model for the Plasticizer, Hexamoll® Diisononyl-Cyclohexane-1, 2-Dicarboxylate Using In Silico, In Vitro, and Human Biomonitoring Data , 2019, Front. Pharmacol..
[5] R. Irizarry. ggplot2 , 2019, Introduction to Data Science.
[6] M. Kolossa-Gehring,et al. Internal exposure of young German adults to di(2-propylheptyl) phthalate (DPHP): Trends in 24-h urine samples from the German Environmental Specimen Bank 1999-2017. , 2019, International journal of hygiene and environmental health.
[7] R. Otter,et al. Corrigendum to "Single ingestion of di-(2-propylheptyl) phthalate (DPHP) by male volunteers: DPHP in blood and its metabolites in blood and urine" [Toxicol. Lett. 294 (2018) 105-115]. , 2018, Toxicology letters.
[8] T. Brüning,et al. Bis-(2-propylheptyl)phthalate (DPHP) metabolites emerging in 24h urine samples from the German Environmental Specimen Bank (1999-2012). , 2015, International journal of hygiene and environmental health.
[9] Céline Helbert,et al. DiceDesign and DiceEval: Two R Packages for Design and Analysis of Computer Experiments , 2015 .
[10] T. Brüning,et al. Urinary metabolite excretion after oral dosage of bis(2-propylheptyl) phthalate (DPHP) to five male volunteers--characterization of suitable biomarkers for human biomonitoring. , 2014, Toxicology letters.
[11] Virunya S Bhat,et al. Derivation of an oral reference dose (RfD) for the plasticizer, di-(2-propylheptyl)phthalate (Palatinol® 10-P). , 2014, Regulatory toxicology and pharmacology : RTP.
[12] Kevin McNally,et al. PopGen: A virtual human population generator. , 2014, Toxicology.
[13] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[14] W. Kessler,et al. Kinetics of di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate in blood and of DEHP metabolites in urine of male volunteers after single ingestion of ring-deuterated DEHP. , 2012, Toxicology and applied pharmacology.
[15] George Loizou,et al. Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation , 2012, Journal of toxicology.
[16] M. Katoh,et al. Metabolite profiling and identification in human urine after single oral administration of DEHP. , 2012, The Journal of toxicological sciences.
[17] T. Brüning,et al. Assessing exposure to phthalates - the human biomonitoring approach. , 2011, Molecular nutrition & food research.
[18] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[19] M. Wittassek,et al. Phthalates: metabolism and exposure. , 2008, International journal of andrology.
[20] Hadley Wickham,et al. Reshaping Data with the reshape Package , 2007 .
[21] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[22] G. Tucker,et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[23] G. Loizou,et al. A human PBPK model for ethanol describing inhibition of gastric motility , 2004, Journal of Molecular Histology.
[24] Ibrahim Chahoud,et al. Blood burden of di(2-ethylhexyl) phthalate and its primary metabolite mono(2-ethylhexyl) phthalate in pregnant and nonpregnant rats and marmosets. , 2004, Toxicology and applied pharmacology.
[25] B. Burchell,et al. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.
[26] A. Saritelli,et al. The in vitro serum protein-binding characteristics of bis-(2-ethylhexyl) phthalate and its principal metabolite, mono-(2-ethylhexyl) phthalate. , 1988, Environmental health perspectives.
[27] N. Di Lascio,et al. Tissue distribution of drug-metabolizing enzymes in humans. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.
[28] U. Bondesson,et al. Effects of di-(2-ethylhexyl) phthalate and five of its metabolites on rat testis in vivo and in in vitro. , 2009, Acta pharmacologica et toxicologica.
[29] T. Orton,et al. Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl) phthalate (DEHP) in rats and marmosets: extrapolation of effects in rodents to man. , 1986, Environmental health perspectives.
[30] B. Lake,et al. Studies on the testicular effects and zinc excretion produced by various isomers of monobutyl-o-phthalate in the rat. , 1981, Chemico-biological interactions.
[31] S. Oishi,et al. Testicular atrophy induced by phthalic acid monoesters: effects of zinc and testosterone concentrations. , 1980, Toxicology.